Salute e Benessere
Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR | MarketsandMarkets™
the liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using NGS segment accounted for the largest share of the market. The large share of this segment is attributed to NGS's ability to analyze multiple genetic alterations simultaneously, offering comprehensive molecular profiling with high accuracy. Its high-throughput capacity, flexibility, and suitability for detecting complex genomic changes make it ideal for clinical applications such as therapy selection and monitoring. The integration of NGS into personalized medicine strategies and its growing use in routine diagnostics further contribute to market growth.
the liquid biopsy market is segmented into cancer and non-cancer applications. In 2024, the cancer applications segment accounted for the largest share of the market. This dominance is primarily driven by the rising global incidence of cancer and the increasing volume of research focused on utilizing liquid biopsy in oncology. The segment's growth is further supported by liquid biopsy's ability to monitor tumor progression in real time, detect minimal residual disease, and overcome limitations associated with traditional tissue biopsies.
, the liquid biopsy market is segmented into five regions: North America , Europe , the Asia Pacific , Latin America , and the Middle East & Africa . In 2024, North America accounted for the largest share of the market. The large share of this market is attributed to the region's well-established healthcare infrastructure, which includes advanced diagnostic capabilities, specialized cancer care centers, and a highly trained medical workforce. These factors collectively support the widespread adoption of liquid biopsy technologies and their integration into routine clinical practice, ensuring broader patient access across diverse healthcare settings.
The leading players operating in this market are Natera, Inc. (US), QIAGEN ( Netherlands ), Guardant Health (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. ( Switzerland ), Thermo Fisher Scientific Inc. (US), GRAIL, Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), and Sysmex Corporation ( Japan ).
Natera, Inc. focuses heavily on R&D capabilities to enhance its portfolio of cell-free DNA-based tests to improve clinical decision-making across oncology, transplant, and reproductive health. Its investments in R&D and capital allocation strategies help fuel its future growth and ability to remain competitive. The company's strategies, including collaborations and acquisitions, aim to solidify its liquid biopsy market position further.
Guardant Health holds a significant share in the liquid biopsy market, supported by its broad distribution network spanning the Americas, Europe , the Middle East & Africa , and Asia Pacific . The company maintains a strong market presence by offering innovative, high-quality products across the entire value chain. Guardant Health emphasizes research and development and pursues organic growth strategies to reinforce its market position. For instance, in June 2025 , the company's Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the US FDA. This blood-based test utilizes methylation analysis to detect various cancers, including bladder, colorectal, lung, and pancreatic, in individuals aged 45 and older at average risk.
For more information,
Get access to the latest updates on and
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, , and . With a , we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our , which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/liquid-biopsy-market-worth-us7-05-billion-by-2030-with-11-8-cagr--marketsandmarkets-302521795.html